A Study of Spatially Fractionated Radiation Therapy Followed by Sequential Hypofractionated or Conventional Fractionated RT Combined With Iparomlimab and Tuvonralimab for Relapsed and Refractory Bulky Solid Tumors
Latest Information Update: 11 May 2026
At a glance
- Drugs Iparomlimab/tuvonralimab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
Most Recent Events
- 05 May 2026 Status changed from not yet recruiting to recruiting.
- 17 Jun 2025 Planned End Date changed from 27 Apr 2029 to 19 Jun 2029.
- 17 Jun 2025 Planned primary completion date changed from 27 Apr 2028 to 19 Jun 2028.